Printer Friendly

CRYOLIFE, INC. FORMS CRYOKIDS FOUNDATION

 DENVER, Aug. 3 /PRNewswire/ -- CryoLife, Inc. (NASDAQ-NMS: CRYL), based in Atlanta, a leader in human tissue engineering and preservation for medical applications, announced that it had jointly formed with the Children's Hospital of Denver, The CryoKids(TM) Foundation.
 The purpose of this non-profit foundation is to fund open heart surgeries for indigent children whose families cannot afford the expense of such surgeries. Candidate preference for funding will be given to children requiring homograft heart valve replacement surgery. Since the founding of CryoLife in 1984, some 9,000 children in North America have been recipients of allograft valves preserved by CryoLife, Inc.
 Under the program of the foundation, surgeons will donate their time and services as will the hospital. CryoLife will pay for any costs that are not reimbursed by third parties.
 Steven G. Anderson, president and chief executive officer of CryoLife, Inc., noted: "We at CryoLife believe we have been very fortunate to be in a business that has had such a dramatic and positive effect on the lives of so many people. The CryoKids Foundation is specifically designed to extend those beneficial results to children who otherwise might not have a chance for a normal life and healthy future."
 David R. Clarke, M.D., chief, Cardiovascular and Thoracic Surgery, Children's Hospital, Denver, added: "Children's Hospital is extremely pleased to be part of this new partnership and gratefully acknowledge the contribution of CryoLife in forming the foundation. Our joint goal is to work toward making this life-saving technology available to needy children."
 It is anticipated that the CryoKids program will be expanded to include a number of foundation chapters throughout the U.S. at institutions whose surgical staff specializes in pediatric cardiovascular surgery.
 Founded in 1984, CryoLife, Inc., is a leader in the development and commercialization of technology for ultra-low temperature preservation ("cryopreservation") of viable human cardiovascular and orthopaedic tissues for transplant. The company uses proprietary or patented processes to disinfect, preserve, store and transport human heart valves, veins and connective tissues for use in cardiac, vascular and orthopaedic surgeries.
 The company is also the exclusive worldwide distributor for Bravo Cardiovascular, Inc., implantable porcine (pig) cardiovascular devices.
 -0- 8/3/93
 /CONTACT; Suzanne Gabbert, assistant corporate secretary of CryoLife, 800-438-8285/
 (CRYL)


CO: CryoLife, Inc.; Children's Hospital of Denver; The CryoKids
 Foundation ST: Colorado, Georgia IN: MTC HEA SU:


BN-RA -- AT007 -- 8904 08/03/93 12:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 3, 1993
Words:397
Previous Article:LINEAR TECHNOLOGY CORPORATION TO BUILD WAFER FABRICATION FACILITY IN CAMAS, WASHINGTON
Next Article:VULCAN AND COMINCO SODA ASH PROJECT PERMITTING ON SCHEDULE
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters